US 12,454,532 B2
Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP)
George Luke, Clinton, CT (US); and Suresh Babu, Ypsilanti, MI (US)
Assigned to FORMA Therapeutics, Inc., Watertown, MA (US)
Filed by FORMATherapeutics, Inc., Watertown, MA (US)
Filed on Sep. 22, 2023, as Appl. No. 18/371,647.
Application 18/371,647 is a continuation of application No. 17/482,717, filed on Sep. 23, 2021, granted, now 11,795,168.
Claims priority of provisional application 63/082,168, filed on Sep. 23, 2020.
Prior Publication US 2024/0150347 A1, May 9, 2024
Int. Cl. C07D 471/04 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 9/1611 (2013.01); A61K 9/1617 (2013.01); A61K 9/1623 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01)] 14 Claims
 
1. A solid form type B of a hydrochloric acid addition salt of a compound of formula (II):

OG Complex Work Unit Chemistry
characterized by an X-ray powder diffraction pattern comprising at least three peak positions (degrees 2θ±0.2) when measured using Cu Kα radiation, selected from the group consisting of: 10.23, 18.72, 23.03, 24.77, and 28.03.